Citi

Dmitry Vinogradov Glaukos Corporation (NYSE:GKOS) traded lower on Wednesday after Citi downgraded the glaucoma product maker to neutral from buy as part of a review of its U.S. MedTech coverage ahead of Q2 2024 results. Analyst Joanne Wuensch argued that Glaukos (GKOS), which has climbed more than 50% this year,Continue Reading

Exchange-traded funds had a strong June, according to Citi Research, as the space was able to pull in net new money on the month. The brokerage compiled the following statistics for the month of June: cross asset funds attracted $75.7B, domestic equity funds amassed a total of $41.2B, global/international equityContinue Reading